Moderate to Severe Atopic Dermatitis

Also known as: Moderate/Severe Atopic Dermatitis / Moderate-to-Severe Atopic Dermatiti / Moderate-to-severe Atopic Dermatitis

DrugDrug NameDrug Description
DB12159DupilumabA monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults.
DB11914LebrikizumabAn IgG4 monoclonal antibody against IL-13 used to treat moderate-to-severe atopic dermatitis in adults and adolescents.
DB12169TralokinumabA monoclonal antibody directed against interleukin-13 which is used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic therapy.
DrugDrug NamePhaseStatusCount
DB15252Nemolizumab2Recruiting1
DB16374Telazorlimab2Completed1
DB12159Dupilumab3Completed1
DB00563Methotrexate3Not Yet Recruiting1
DB15252Nemolizumab3Active Not Recruiting1
DB15252Nemolizumab3Completed2
DB15252Nemolizumab3Withdrawn1
DB12159Dupilumab4Recruiting1
DB00864Tacrolimus4Completed1
DB00091CyclosporineNot AvailableCompleted1
DB12159DupilumabNot AvailableCompleted1
DB00337PimecrolimusNot AvailableCompleted1
DB01130PrednicarbateNot AvailableCompleted1
DB00860PrednisoloneNot AvailableCompleted1
DB00864TacrolimusNot AvailableCompleted1